Daytrana gains indication for attention deficit hyperactivity disorder (ADHD) in adolescents

The FDA has approved Daytrana (methylphenidate transdermal system, from Shire) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents 13–17 years of age. This approval was based on results from a Phase 3b multicenter, 7-week, randomized, double-blind, placebo-controlled study in 217 adolescents aged 13–17 years diagnosed with ADHD. Patients treated with Daytrana demonstrated a significant reduction in ADHD Rating Scale-IV total score from baseline to endpoint compared with placebo (p<0.001).

Daytrana is already approved for the treatment of ADHD in children 6–12 years of age. It is available in 10mg, 15mg, 20mg, and 30mg dosage strengths.

For more information call (800) 828-2088 or visit www.daytrana.com.